Why Isoform-Specific TGF-β Measurement Matters

TGF-β represents a unique measurement challenge in biomarker research. Unlike classical cytokines that are actively secreted upon stimulation, TGF-β is constitutively produced as a latent complex — non-covalently bound to latency-associated peptide (LAP) — that must be released by acidification, proteolytic cleavage, or integrin-mediated activation to become biologically active. Most immunoassays detect only the active fraction or only after acid activation (total TGF-β). The TGF-β 3-Plex measures total TGF-β1, TGF-β2, and TGF-β3 after standardized acid activation — providing the total pool of each isoform available for biological activity. The distinction between isoforms is critical: TGF-β1 is the dominant pro-fibrotic isoform targeted by fresolimumab and multiple investigational anti-fibrotic therapies; TGF-β2 is the dominant isoform in aqueous humor and vitreous, regulating ocular immune privilege; TGF-β3 promotes scarless wound healing in fetal tissue and is being investigated as an anti-scarring therapeutic (avotermin). Measuring only TGF-β1 — as most single-plex ELISAs do — misses the isoform-specific biology that determines whether the TGF-β response drives fibrosis, immune tolerance, or regenerative repair.

TGF-β Isoforms — Biological Functions & Research Relevance

  • TGF-β1 — Master Pro-Fibrotic Cytokine: drives epithelial-mesenchymal transition (EMT), myofibroblast differentiation, and extracellular matrix deposition. Elevated across fibrotic diseases: IPF (lung), NASH/cirrhosis (liver), CKD (kidney), SSc (skin), cardiac fibrosis. Target of fresolimumab (anti-TGF-β) and galunisertib (TGF-βRI kinase inhibitor). LOD in U-PLEX format: ~9.1 pg/mL.
  • TGF-β2 — Ocular & Neuronal Isoform: the dominant TGF-β in aqueous humor and vitreous, maintaining anterior chamber immune privilege. Critical in cardiac valve development and neuronal survival. Elevated in proliferative vitreoretinopathy and glaucoma. LOD: ~2.5 pg/mL.
  • TGF-β3 — Regenerative Isoform: promotes scarless fetal wound healing through reduced collagen deposition and altered hyaluronan matrix organization. Investigated as avotermin (recombinant TGF-β3) for scar reduction in research studys. Essential for palatogenesis — TGF-β3 knockout mice have cleft palate. LOD: ~1.4 pg/mL.
  • BDNF (Brain-Derived Neurotrophic Factor): neurotrophin supporting neuronal survival, synaptic plasticity (LTP), and hypothalamic energy homeostasis. Decreased in major depression; increased by exercise and SSRI treatment. Serum BDNF is a research biomarker in psychiatry and metabolic disease.
  • β-NGF (beta-Nerve Growth Factor): the prototypical neurotrophin supporting sensory and sympathetic neuron survival. Target of tanezumab (anti-NGF monoclonal antibody) for osteoarthritis and chronic low back pain. Elevated in chronic pain conditions.
  • FGF-21 (Fibroblast Growth Factor 21): hepatokine-adipokine with insulin-sensitizing and weight-loss effects. Paradoxically elevated in NAFLD/NASH — reflecting FGF-21 resistance. FGF-21 analogs (efruxifermin, pegozafermin) in Phase 3 trials for NASH.